TMCI vs PRCT

For growth investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger pick with 37.

2% revenue growth year-over-year, versus 1. 6% for Treace Medical Concepts, Inc. (TMCI). Analysts rate PROCEPT BioRobotics Corporation (PRCT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, PROCEPT BioRobotics Corporation (PRCT) delivered a total return of -39.

3%, compared to -94. 1% for Treace Medical Concepts, Inc. (TMCI). Over 10 years, the gap is even starker: PRCT returned -39. 4% versus TMCI's -92. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PROCEPT BioRobotics Corporation (PRCT) is the lower-risk stock at 1.

14β versus Treace Medical Concepts, Inc. 's 2. 19β — meaning TMCI is approximately 92% more volatile than PRCT relative to the S&P 500. On balance sheet safety, PROCEPT BioRobotics Corporation (PRCT) carries a lower debt/equity ratio of 14% versus 16% for Treace Medical Concepts, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PROCEPT BioRobotics Corporation (PRCT) is pulling ahead at 37.

2% versus 1. 6% for Treace Medical Concepts, Inc. (TMCI). On earnings-per-share growth, the picture is similar: PROCEPT BioRobotics Corporation grew EPS 1. 7% year-over-year, compared to -3. 3% for Treace Medical Concepts, Inc.. Over a 3-year CAGR, PRCT leads at 60. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Treace Medical Concepts, Inc.

(TMCI) is the more profitable company, earning -27. 7% net margin versus -31. 0% for PROCEPT BioRobotics Corporation — meaning it keeps -27. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMCI leads at -25. 5% versus -33. 7% for PRCT. At the gross margin level — before operating expenses — TMCI leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

14)). Treace Medical Concepts, Inc. (TMCI) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRCT: -39. 4%, TMCI: -92. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TMCI is a small-cap quality compounder stock; PRCT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.